All In Biotech

Drug Trial Radar · NCT06973564

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 Monotherapy and in Combination With Other Agents in Adult Patients With Advanced Solid Tumors With KRAS Alteration

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

344

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Nov 2028

Study completion Feb 2029

Sponsor

Sponsor type
Industry
Collaborators
AstraZeneca
First posted
May 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • JAB-23E73Drug

    Oral administration

  • CetuximabDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number and proportion of patients who experience at least 1 dose-limiting toxicity (DLT) with treatment of JAB-23E73 monotherapy.Time frame: Up to 1 year
  2. Part A: Safety and tolerability of JAB-23E73 monotherapyTime frame: Up to 2 years
  3. Part A: Objective response rate (ORR) of JAB-23E73 monotherapy.Time frame: Up to 3 years
  4. Part B1: Safety, tolerability and RP2D of JAB-23E73 in combination with cetuximab.Time frame: Up to 2 years
  5. Part B1: Objective response rate (ORR) of JAB-23E73 in combination with cetuximab.Time frame: Up to 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.